Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life

References

• Headache Classification Committee of the International Headache S. The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 2013;33:629–808. Epub 2013/06/19.
   PubMed Web of Science ®Google Scholar
• Natoli JL, Manack A, Dean B, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30:599–609. Epub 2009/07/21
   PubMed Web of Science ®Google Scholar
• Bigal ME, Serrano D, Reed M, et al. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology. 2008;71:559–566. Epub 2008/08/20
   PubMed Web of Science ®Google Scholar
• Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011;31:301–315. Epub 2010/09/04
   PubMed Web of Science ®Google Scholar
• Buse DC, Manack A, Serrano D, et al. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry. 2010;81:428–432. Epub 2010/02/19
   PubMed Web of Science ®Google Scholar
• GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.Lancet. 2016;388:1545–1602. Epub 2016/10/14
   PubMed Web of Science ®Google Scholar
• Dodick DW, Loder EW, Manack Adams A, et al. Assessing barriers to chronic migraine consultation, diagnosis, and treatment: results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study.
   Google Scholar
• Cevoli S, D’Amico D, Martelletti P, et al. Underdiagnosis and undertreatment of migraine in Italy: a survey of patients attending for the first time 10 headache centres. Cephalalgia. 2009;29:1285–1293. Epub 2009/05/15
   PubMed Web of Science ®Google Scholar
• Hepp Z, Rosen NL, Gillard PG, et al. Comparative effectiveness of onabotulinumtoxinA versus oral migraine prophylactic medications on headache-related resource utilization in the management of chronic migraine: retrospective analysis of a US-based insurance claims database. Cephalalgia. 2016;36:862–874. Epub 2015/12/23
   PubMed Web of Science ®Google Scholar
• Hepp Z, Bloudek LM, Varon SF. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm. 2014;20:22–33. Epub 2014/01/01
   PubMed Web of Science ®Google Scholar
• Sarchielli P, Granella F, Prudenzano MP, et al. Italian guidelines for primary headaches: 2012 revised version. J Headache Pain. 2012;13(Suppl 2):S31–70. Epub 2012/05/18
   PubMed Web of Science ®Google Scholar
• Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30:793–803. Epub 2010/07/22
   PubMed Web of Science ®Google Scholar
• Aurora SK, Winner P, Freeman MC, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51:1358–1373. Epub 2011/09/03
   PubMed Web of Science ®Google Scholar
• Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30:804–814. Epub 2010/07/22
   PubMed Web of Science ®Google Scholar
• Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50:921–936.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Rosen NL, Ailani J, et al. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: pooled results from the PREEMPT randomized clinical trial program. Cephalalgia. 2016;36:899–908. Epub 2016/06/12
   PubMed Web of Science ®Google Scholar
• Botox. Summary of Product Characteristics
   Google Scholar
• NICE. Botulinum toxin type A for the prevention of headache in adults with chronic migraine. Available at https://www.nice.org.uk/guidance/ta260. Accessed 2017 Aug 7
   Google Scholar
• Tassorelli C, Aguggia M, de Tommaso M, et al. Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers. J Headache Pain. 2017;18:66. Epub 2017/ 07/02
   PubMed Web of Science ®Google Scholar
• Aicua-Rapun I, Martinez-Velasco E, Rojo A, et al. Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin A during more than one year. J Headache Pain. 2016;17:112.
   PubMed Web of Science ®Google Scholar
• Boudreau GP, Grosberg BM, McAllister PJ, et al. Prophylactic onabotulinumtoxinA in patients with chronic migraine and comorbid depression: an open-label, multicenter, pilot study of efficacy, safety and effect on headache-related disability, depression, and anxiety. Int J Gen Med. 2015;8:79–86. Epub 2015/03/04
   PubMed Web of Science ®Google Scholar
• Butera C, Colombo B, Bianchi F, et al. Refractory chronic migraine: is drug withdrawal necessary before starting a therapy with onabotulinum toxin type A? Neurol Sci. 2016;37:1701–1706.
   PubMed Web of Science ®Google Scholar
• Cernuda-Morollon E, Ramon C, Larrosa D, et al. Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: what happens after one year? Cephalalgia. 2015;35:864–868.
   PubMed Web of Science ®Google Scholar
• Demiryurek BE, Ertem DH, Tekin A, et al. Effects of onabotulinumtoxinA treatment on efficacy, depression, anxiety, and disability in Turkish patients with chronic migraine. Neurol Sci. 2016;37:1779–1784. Epub 2016/07/16
   PubMed Web of Science ®Google Scholar
• Grazzi L. Onabotulinumtoxin A for chronic migraine with medication overuse: clinical results of a long-term treatment. Neurol Sci. 2017;38: 141–143. Epub 2017/05/21
   PubMed Web of Science ®Google Scholar
• Grazzi L, Usai S. Onabotulinum toxin A (Botox) for chronic migraine treatment: an Italian experience. Neurol Sci. 2015;36(Suppl 1):33–35.
   PubMed Web of Science ®Google Scholar
• Guerzoni S, Pellesi L, Baraldi C, et al. Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatment. J Headache Pain. 2015;17:48.
   PubMed Web of Science ®Google Scholar
• Khalil M, Zafar HW, Quarshie V, et al. Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, U.K. J Headache Pain. 2014;15:54.
   PubMed Web of Science ®Google Scholar
• Kollewe K, Escher CM, Wulff DU, et al. Long-term treatment of chronic migraine with OnabotulinumtoxinA: efficacy, quality of life and tolerability in a real-life setting. J Neural Transm (Vienna). 2016;123:533–540. Epub 2016/04/02
   PubMed Web of Science ®Google Scholar
• Negro A, Curto M, Lionetto L, et al. OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study. Springerplus. 2015;4:826. Epub 2016/01/12
   PubMed Web of Science ®Google Scholar
• Negro A, Curto M, Lionetto L, et al. A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience. J Headache Pain. 2015;17:1.
   PubMed Web of Science ®Google Scholar
• Pedraza MI, De La Cruz C, Ruiz M, et al. OnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigm. Springerplus. 2015;4:176. Epub 2015/04/22
   PubMed Web of Science ®Google Scholar
• Russo M, Manzoni GC, Taga A, et al. The use of onabotulinum toxin A (Botox((R))) in the treatment of chronic migraine at the Parma Headache Centre: a prospective observational study. Neurol Sci. 2016;37:1127–1131.
   PubMed Web of Science ®Google Scholar
• Silberstein S, Tfelt-Hansen P, Dodick DW, et al. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia. 2008;28:484–495. Epub 2008/02/26
   PubMed Web of Science ®Google Scholar
• Gooriah R, Ahmed F. OnabotulinumtoxinA for chronic migraine: a critical appraisal. Ther Clin Risk Manag. 2015;11: 1003–1013. Epub 2015/07/15
   PubMed Web of Science ®Google Scholar
• Dodick DW, Turkel CC, DeGryse RE, et al. Assessing clinically meaningful treatment effects in controlled trials: chronic migraine as an example. J Pain. 2015;16:164–175. Epub 2014/12/03
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Dodick DW, Aurora SK, et al. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT. J Neurol Neurosurg Psychiatry. 2015;86:996–1001. Epub 2014/12/17
   PubMed Web of Science ®Google Scholar
• Eross EJ, Gladstone JP, Lewis S, et al. Duration of migraine is a predictor for response to botulinum toxin type A. Headache. 2005;45:308–314. Epub 2005/04/20
   PubMed Web of Science ®Google Scholar
• Lee MJ, Lee C, Choi H, et al. Factors associated with favorable outcome in botulinum toxin A treatment for chronic migraine: a clinic-based prospective study. J Neurol Sci. 2016;363:51–54. Epub 2016/03/24
   PubMed Web of Science ®Google Scholar
• Dominguez C, Pozo-Rosich P, Torres-Ferrus M, et al. OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study. DOI:10.1111/ene.13523
   Google Scholar
• Castrillo Sanz A, Morollon Sanchez-Mateos N, Simonet Hernandez C, et al. Experience with botulinum toxin in chronic migraine. Neurologia. 2016. Epub 2016/10/26. DOI:10.1016/j.nrl.2016.09.004
   Google Scholar
• Aurora SK, Brin MF. Chronic migraine: an update on physiology, imaging, and the mechanism of action of two available pharmacologic therapies. Headache. 2017;57: 109–125. Epub 2016/12/03
   PubMed Web of Science ®Google Scholar
• Manack AN, Buse DC, Lipton RB. Chronic migraine: epidemiology and disease burden. Curr Pain Headache Rep. 2011;15: 70–78. Epub 2010/11/11
   PubMed Web of Science ®Google Scholar
• Serrano D, Lipton RB, Scher AI, et al. Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J Headache Pain. 2017;18:101. Epub 2017/10/06
   PubMed Web of Science ®Google Scholar
• Tassorelli C, Jensen R, Allena M, et al. The added value of an electronic monitoring and alerting system in the management of medication-overuse headache: a controlled multicentre study. Cephalalgia. 2017;37:1115–1125. Epub 2016/07/22
   PubMed Web of Science ®Google Scholar
• Blumenfeld AM, Schim JD, Chippendale TJ. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Headache. 2008;48: 210–220. Epub 2007/12/01
   PubMed Web of Science ®Google Scholar
• Mathew NT, Jaffri SF. A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study. Headache. 2009;49: 1466–1478. Epub 2009/11/17
   PubMed Web of Science ®Google Scholar
• Magalhaes E, Menezes C, Cardeal M, et al. Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine. Clin Neurol Neurosurg. 2010;112:463–466. Epub 2010/04/20.
   PubMed Web of Science ®Google Scholar
• Diener HC, Holle D, Solbach K, et al. Medication-overuse headache: risk factors, pathophysiology and management. Nat Rev Neurol. 2016;12:575–583. Epub 2016/09/13
   PubMed Web of Science ®Google Scholar
• May A, Schulte LH. Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol. 2016;12: 455–464. Epub 2016/07/09
   PubMed Web of Science ®Google Scholar
• Tassorelli C, Jensen R, Allena M, et al. The added value of an electronic monitoring and alerting system in the management of medication-overuse headache: a controlled multicentre study. Cephalalgia. Cephalalgia. 2017 Oct;37(12):1115-1125. Epub 2016/07/22
   Web of Science ®Google Scholar
• Bigal ME, Serrano D, Buse D, et al. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 2008;48:1157–1168. Epub 2008/09/24
   PubMed Web of Science ®Google Scholar
• Lipton RB, Bigal ME. Chronic daily headache: is analgesic overuse a cause or a consequence? Neurology. 2003;61: 154–155. Epub 2003/07/23
   PubMed Web of Science ®Google Scholar
• Munksgaard SB, Bendtsen L, Jensen RH. Modulation of central sensitisation by detoxification in MOH: results of a 12-month detoxification study. Cephalalgia. 2013;33: 444–453. Epub 2013/02/23
   PubMed Web of Science ®Google Scholar
• Perrotta A, Arce-Leal N, Tassorelli C, et al. Acute reduction of anandamide-hydrolase (FAAH) activity is coupled with a reduction of nociceptive pathways facilitation in medication-overuse headache subjects after withdrawal treatment. Headache. 2012;52:1350–1361. Epub 2012/06/08
   PubMed Web of Science ®Google Scholar
• Evers S, Jensen R. European Federation of Neurological S. Treatment of medication overuse headache–guideline of the EFNS headache panel. Eur J Neurol. 2011;18: 1115–1121. Epub 2011/08/13
   PubMed Web of Science ®Google Scholar
• Rossi P, Jensen R, Nappi G, et al. A narrative review on the management of medication overuse headache: the steep road from experience to evidence. J Headache Pain. 2009;10:407–417. Epub 2009/10/06
   PubMed Web of Science ®Google Scholar
• Chiang CC, Schwedt TJ, Wang SJ, et al. Treatment of medication-overuse headache: a systematic review. Cephalalgia. 2016;36:371–386. Epub 2015/07/01
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Blumenfeld AM, Cady RK, et al. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci. 2013;331:48–56. Epub 2013/06/25
   PubMed Web of Science ®Google Scholar
• Ahmed F, Zafar HW, Buture A, et al. Does analgesic overuse matter? Response to OnabotulinumtoxinA in patients with chronic migraine with or without medication overuse. Springerplus. 2015;4:589. Epub 2015/11/07
   PubMed Web of Science ®Google Scholar
• Hubbard CS, Becerra L, Smith JH, et al. Brain changes in responders vs. non-responders in chronic migraine: markers of disease reversal. Front Hum Neurosci. 2016;10:497.
   PubMed Web of Science ®Google Scholar
• Cernuda-Morollón E, Martínez-Camblor P, Ramón C, et al. CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine. Headache. 2014;54:987–995.
   PubMed Web of Science ®Google Scholar
• Dominguez C, Vieites-Prado A, Perez-Mato M, et al. CGRP and PTX3 as predictors of efficacy of onabotulinumtoxin Type A in chronic migraine: an observational study. Headache. 2017. Epub 2017/11/14. DOI: 10.1111/head.13211
   PubMedGoogle Scholar
• Barbanti P, Ferroni P. Onabotulinum toxin A in the treatment of chronic migraine: patient selection and special considerations. J Pain Res. 2017;10: 2319–2329. Epub 2017/10/17
   PubMed Web of Science ®Google Scholar
• Jakubowski M, McAllister PJ, Bajwa ZH, et al. Exploding vs. imploding headache in migraine prophylaxis with Botulinum Toxin A. Pain. 2006;125:286–295. Epub 2006/10/31
   PubMed Web of Science ®Google Scholar
• Sandrini G, Perrotta A, Tassorelli C, et al. Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study. J Headache Pain. 2011;12:427–433. Epub 2011/04/19
   PubMed Web of Science ®Google Scholar
• Blumenfeld AM, Aurora SK, Laranjo K, et al. Unmet clinical needs in chronic migraine: rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine. BMC Neurol. 2015;15:100. Epub 2015/07/03
   PubMed Web of Science ®Google Scholar
• Davies B, Gaul C, Martelletti P, et al. Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data. J Headache Pain. 2017;18:93. Epub 2017/09/08
   PubMedGoogle Scholar